 print
version
Professor Ana Aslan
and Gerovital-H3, the Original and First Anti-Aging Medicine
By
Mircea Dumitru MD Ph.D. (by Ana Aslan's personal physician).
Who was Ana Aslan?
Ana Aslan is renowned for her essential contribution
to gerontological research as well as for having patterned the best geriatric
treatment influencing the aging process. Ana Aslan was the first person to rule
out the fatalistic approach to aging, providing a new method in gerontology by
opening the way to the prevention and treatment of old age.
I worked
with Professor Ana Aslan for 25 years, from 1963, first as a researcher, then
as chief physician and afterwards as the Director of the National Institute of
Gerontology and Geriatrics in Bucharest, Romania, between 1978 and 1990.
In the last 3 years of her life, Aslan chose me as her personal physician and
three months before her death she asked me to do some personal things, including
to write a book about her life and her work. So I took notes at her bedside as
a moral testament.
In addition to her life, she talked of her views of
politics, religion, euthanasia, dying, death and love. As such I had the opportunity
to know her private thoughts and personal thinking.
On her 90th solemn
birthday celebration at the Romanian Academy in Bucharest on May 22nd, 1987, on
behalf of the Romanian National Institute of Gerontology and Geriatrics, I said;
"I want to express my emotion and say how difficult it is to talk about Ana
Aslan, being such a complex personality, the story of Gerontology might as well
be the story of Aslan."
"Ana Aslan's life can be seen in her
work. She has battled courageous fights, all for the service of good, to make
man's dream to live with dignity for as long as possible. Now we celebrate the
inventor, the scientist, the physician, and the professor. For 35 years since
1952, she has led us as the first Institute of Gerontology in the world. Ana Aslan
is the Ambassador of Gerontology and a brilliant woman.
As a scientist
she is an inventor, not an imitator. She has played such an important role in
Gerontology at the world level. She has given the world decades of research that
revealed that Gerovital-H3 is the most effective treatment in geriatrics. Ana
Aslan is the original contributor in the basic research concerning cellular and
molecular aging, and researching her product reaction in the body.
She
has a special empathy for the elderly and has always fought to improve their condition
all over the world. She worked with others to initiate the General Assembly of
the United Nations Organization on aging, held in Vienna, 1983. Aslan has a remarkable
understanding and appreciation for beauty and culture. At one time she visited
Hippocrates grave and on which she stated, "I now realize how small I am."
As a disciple and collaborator, and being inspired by the University Hymn,
I declare "Viva Academia! Viva Professores! Viva Ana Aslan!"
Aslan's distinctions
1. Commander of the order "Meritor Della
Republica," Italy, 1969
2. Commemorative Gold Medal, Nicaragua, 1971.
3. Cross of Merit, first class Order of Merit, Germany, 1971.
4. Hero of Socialist
Labor, Romania, 1971.
5. "Augusto Pinaud," Medal, Venezuela, 1972.
6. Cavalier de la Nouvelle Europe, Prize Oscar, Italy, 1973.
7. Knight of
the Order "Les Palmes Academiques," France, 1974.
8. International
Prize, "Eva," Italy, 1974.
9. Commander of the Order "De Orange
Nassau," Holland, 1975.
10. "L'Ordre du Merite," Grande Officier,
Senegal, 1976.
11. "Dag Hamarskjoeld," International Prize, Italy,
1977.
12. "Dama di Collare Del Santo Graal," Nice, 1978 (granted
by Italy)
13. Honorary Foreign Citizen and Honorary Professor of Sciences,
Manila, Philippines, 1978.
14. President and Honorary Guest of the Symposium,
"Ageing Comes of Age," Philippines Academy, Philippines Association
of Geriatrics and Gerontology, 1978.
15. Officer of the Order "Merito
Della Republica Italiana," 1979.
16. La Medaille et le Prix "Leon
Bernard" La 35eme Assemblee Mondiale de la Sante, 1982.
Aslan is
quoted in all of the following
Who's Who in America (1972) Who's Who in the
World (1971) Who's is Who of Women (1971) British Encyclopaedia (1974) Who's Who
of Intellectuals (1976) The International Men of Achievement (1976) International
Biographical Association of England (1978)
Dr. Dumitru comments
We are witnessing a spectacular alteration of the age pyramid. Furthermore the
process of the demographic aging of the population will continue to increase in
the coming decades. I feel obliged to sound an alarm at the apparition of this
phenomenon unique in human history, at least in relation to how the appropriate
tactics and strategies should be adopted.
Human society has the duty
to benefit in an organised way from the knowledge, experience, wisdom and the
free time of the elderly.
Activity, as a way of life for aging and aged
people, creates for them a mental and physical well being, changing old age into
a useful period, not only at the individual and family level, but at the social
level too.
The traditional image of the elderly incapable of working,
needing help, care and with a tendency for solitude is being reevaluated. Elderly
people do not appear as a homogenous category of population, but as a very heterogeneous
one, from the demographic, medical and social standpoint.
The concept
of the "elderly" from the social standpoint is becoming outworn and
out-of-fashion, and is frequently considered in a merely functional sense related
to the elderly's capacity of assuming a role in the community.
Interdisciplinary
researches are apt to offer solutions for promoting an Active Old Age. As a supporter
of an optimistic conception of the third age, in the data that I am submitting,
I will propose measures to forming a new attitude towards this last stage of life.
"The everlasting ageless youth" has always been one of the great
desires and concerns of mankind. Especially in the latter decades, if the thoughts
of the last thousand years were put into a microscopic lens then the complex equation
of human aging would begin to reveal some of its unknown values, however man cannot
accept the idea of aging and death.
I have discussed the topics of aging
and old age with my patients during the last 40 years of my pregeriatric and geriatric
practice; these years having been dedicated to scientific research relating to
the aging diseases; their prevention and treatment.
I worked for 25 years
at the National Institute of Gerontology and Geriatrics in Bucharest, of which
I was the Director and the closest coworker of the famous Romanian physician-
Ana Aslan for 11 years. I have had the opportunity to examine patients of different
ages from all over the world, to know their thoughts, their concerns and their
varied questions.
For example, I've talked with many young people, for
whom aging, death and disease were states, which they hadn't accepted yet as a
possibility during their life. Other young people I have dealt with had diseases
and pain and wished an end as quickly as possible. Some considered that they ought
to try everything as soon as possible and had no respect for their health.
Some women believed the menopause was the starting of their old age and other
healthy old (often-centenarian) people who were in full activity pleaded for the
beauty of this age and regarded life from the height of their wisdom. Of course
there were also their children abandoned those elderly who had severe chronic
diseases and were living alone having. All this has been a fantastic lesson for
my pregeriatric and geriatric practice.
But only fate made me the personal
physician of Professor Ana Aslan during the last three years of her life. During
this time we became closer in spirit and in our long conversations she shared
many of her private thoughts of her life experience fighting against old age and
its sufferings.
Asking her many questions that I was concerned about
gave me the opportunity to learn the convictions of one of the most famous personalities
in the world, her ideas were pioneering in the fascinating field of Gerontology
and Geriatrics.
In the afternoons and in the evenings on the terrace
of her apartment at the Otopeni Clinic, (where she was convalescing), she told
me her thoughts, and interrupted only by nightingale trills, she talked of the
84 countries she had visited. The people, their cultures, the famous personalities
she'd met, and normally, about the history of her only son- Gerovital-H3- the
product that could improve the quality of life.
After 40 years of age
(which is a critical period from a biological point of view), many people begin
to ask; "What is old age? What about the aging process? How can we fight
against it? Can old age be delayed or prevented? What are the factors accelerating
the aging process? Should we learn to die? Has a person the right to dispose of
his or her own life and decide when the end is to be? What about sexual activity
in old age? Can it be improved? How will relations between the generations be
affected? What is the older persons role in society and family?" and so on.
My understanding of the concerns of gerontology schools in the United States,
Great Britain, Germany, France and Romania regarding the "Life Extension
Research" and from my geriatric practice, in time, I appreciated that "those
good habits" give strength and active life in aging.
Today we have
discovered what was originally thought to be a compulsory condition of old age,
namely the presence of heart disease, arthritis, diabetes, depression. Presently
and especially in the near future these are (and will) no longer are the facts
of aging. Everything depends on the way you live from birth to death and what
kind of supplements you are taking.
The behaviour is based on the way
of thinking to remain young, on the strategy to fight against gaining weight,
to prevent paralysis, to fight against the stress and to maintain a young at heart
spirit.
In the following pages, I will try to answer some of these questions
and to draw the way to live, remain active and to retain dignity in older age.
"To grow old in a beautiful and dignified way is at the same time a
science and an art." Ana Aslan.
The aging process and old age
Ana Aslan remembered with pleasure a question asked by many reporters and research
workers; "What made you in the 1940's- when very few people thought about
geriatrics- dedicate yourself to the study of aging and to the care of old people?"
Ana Aslan's answer was always full of nostalgia; "At the age of 50 I
changed my career and I started another life dedicated to Geriatrics. I was a
specialist in Internal Medicine and Cardiology and in 1945 on January 1st, I received
a congratulation card, which I keep with my precious possessions. This card was
signed by many of my patients who wrote- On the occasion of your birthday a group
of old patients, some of life's broken toys, wish you good health and many happy
years! - I read and re-read- these words many times and they continued to stir
me and even to obsess me. I told myself, that in fact, these broken toys could
be mended, and I wondered what help I could give old people? Those words and that
card, together with the impulse given by one of my professor's, were the seed
which sprang in my mind and made me dedicate the rest of my life to the study
and treatment of old people. It was the elderly showed me that TIME is the killer
of organic substance and it puts its definite imprint on the human organism."
In our contemporary society, we are witnessing two essential tendencies,
the aging population and the technical progress.
The understanding of
demographic tendencies, therapy and recovery from the diseases of old age are
priority problems with economical, political and social implications.
Each of us is a witness to a spectacular increase of the average life span, which
increased from 40-50 years in the last century, and now, to more than 78 years
old. Grandfathers take care of their grandchildren, and their great grandchildren,
and they share with them their life experience, a feat not possible before in
the history of mankind.
In the year 2000 those over 60 years old will
represent 15-20% of the total population of the earth. The rate of those over
65 increased from 200 millions in 1950's to 400 millions in 1985, and to an estimated
600 millions in 2000, and to more than 1 billion in 2025!
What are the
implications of the presence of such a segment of elderly within the population?
Should they stay outside of the normal social life? The answer to these questions
has an impact not only on Gerontology, but in philosophy, religion, politics and
economy too. Geriatrics deals with the medicine for the elderly, and Gerontology
studies the modifications of the human organism in time, as such Gerontology can
define the aging process and can distinguish between aging and disease. Alone
they cannot answer and solve the fundamental aging questions, but together they
become a powerful science.
* Aging is a plurality of normal changes of
mankind due to the lapse of time, the change in the frame of mind and in the physical
condition of each of us. * Disease is an accident, a pathological process, abnormal,
which can occur occasionally in childhood, adulthood and is not compulsory in
old people.
Disease can be prevented, treated, or if it becomes chronic
it can be alleviated. Disease can also often hide aging and for this reason we
should pay attention to the change due to time "per se."
The
aging process is suggestively illustrated in Figure 4. It shows the increasing
presence of aging from the period of embryo, childhood, adulthood and into old
age. In this conception, old age is the last period of the life, when the aging
signs become evident; signs such as the gerontoxon (or arcus senilis), a degenerative
change in the cornea occurring in persons over the age of 50 and the ceasing of
the menstrual cycle etc.
For the reader it is very important to know
that aging is subjected to the influence of genetic and environmental factors.
Under the influence of these factors, the aging rhythm can be normal, accelerated,
or delayed.
Each person has his or her own biological clock, which can
function normally, or it may have an accelerated or delayed function.
The nutrition, physical, environmental factors, way of life, presence or absence
of diseases, stress and the eutrophic treatment with Gerovital-H3 influences the
aging rhythm.
After the age of 40, the proportion between muscular and
fat tissue changes. Around the age of 60- 30% of the muscular mass is replaced
by fat tissue. The articular flexibility, muscular strength, pulmonary ventilation,
vascular elasticity and cardiac efficiency decrease with advancing age.
Visual acuity and ovarian function are among the first changes, which announce
the period of senescence. In bone structure, important changes take place, which
should be prevented with the necessary steps.
At the age of 65 we can no longer
do what we did at the age of 30 and this fact we all understand.
Old age is
often a "state of mind" and the human spirit is the strongest treatment,
which should be fed with understanding, useful constructive work, love, tolerance,
kindness and friendship.
Old age can be a period of pain, loneliness
and disease, with high medical cost and social complexity; Grieg described it
as "diminishing also has its beauty," Juvenal however, said, "old
age is worse than death."
In everyday life, in literature, in fairy
tales, old age aureole is not missing. In popular wisdom, the old man appears
as a positive character, kind and clever. The elderly are capable of useful activities
for themselves and for others, they can solve difficult situations, to value their
creativity. They are a treasure of wisdom and preserve a "living history,"
they are the keepers of history, and by vocation, character and inspired choice,
become as much important as inventors.
When I asked Aslan, "what
is aging and old age and how do we fight it?" she answered, "Old age
is full of suffering and pain and I regard this as a parasite of life which develops
slowly and whether you know it or not, it takes hold of us. From the age of 50
onward, I declared war on aging and old age. Gerontology and Geriatrics have enough
possibilities to slow down the aging process and to delay old age onset. We are
obliged to guard against and to explain to healthy or sick patients, what it means
to grow old, and what they have to do in order to extend their life in conditions
of quality. My treatment and my method is a solution, Gerovital-H3 is not only
a treatment, it is hope, and when there is no hope, there is nothing."
Ana Aslan's incredible adventure
(IN HER OWN WORDS) "I accepted
that I had to leave Bucharest in order to be by myself. This was not easy for
me, but in those years, the air that I was breathing was not enough. Brilliant
lights are attractive to creative spirits, but they can also deprive you of sight.
The magnificent oaks have too much shade, and under their magnificent crown
you can find the smallest trees. Their seeds should be taken by the wind to fertile
places."
Ana Aslan had many personal ideas, one of which was to
start a medical school in Timisoara, the western Romanian town situated on the
banks of the Bega channel.
It was here that she met Dr. Pius Branzeu,
a student under the famous Professor Loriche. She discussed his methods of Novocain
treatments on post-operative incisions and later learned about Dos Ghali's method
of intravenous administration of Novocain in patients with bronchial asthma.
Ana Aslan passionately studied Professor C.I. Parhon's work as well. After
30 years of clinical and experimental observations, Parhon reached the conclusion
that aging is a disease and that it can be treated. In 1908 he published his observations
of two cases of senile ostemalacia and in 1925, he introduced the term Ilikibiology,
meaning morphological, chemical and physiological variations related to age.
"I taught at the medical clinic in Timisoara and learned the basic notions
of gerontology. I read all the works of Marinescu, Parhon, Metchnikoff, Charcot
and Burger (the principle disciples of gerontology) and I also maintained a relationship
with Dr. Parhon. Since 1946, he was the Director of the Institute of Endocrinology
in Bucharest and the chair of the Endocrinology Department of the University there.
I returned to Bucharest once a month just to talk to him."
"Parhon
was a pioneer in gerontology. He treated aging patients with extracts of epiphysis,
gonads, insulin and vitamin E, in 1909 he published the first book in the world
of endocrinology and in 1955 published the book Biology of Ages, which was translated
all over the world."
"Parhon had a universal mind and was a
wonderful man. Our privileged relationship was in the field of gerontology; this
was where his heart was. He believed in rejuvenating and ardently maintained that
life cannot be only a one-way direction. He knew everything, botany, zoology,
endocrinology, psychiatry and anthropology. His mind was like an encyclopaedia!
Above all, Parhon was a man of great generosity and dedication. He sacrificed
many things for medicine, even including some family relationships, he was quite
different from Danielopolu but without the two, I would not be what I am now!"
In 1946, Aslan published her first research on Novocain, The Novocain Action
on the Respiratory Rate when injected in the Human. "After the first results
with Novocain injections in the vascular embolias, I tried this treatment on patients
with arthosis and those with a tendency to ankylosis. Because these diseases are
chronic, I administered each with more injections. With great joy, I noticed an
improvement in the local symptoms, and even more importantly, a great improvement
in their overall general condition. Before the treatments, the patients avoided
any movement due to pain, and then they were willing and wanting to walk, sit
up and read, and talk. The biggest reward was to notice an increase in their interest
in life and for their families."
"These improvements also came
along with much more restful sleep for the patients. This led me to the hypothesis
on Novocain's general effect on the neurophysical system. Maybe it had effects
here as well as locally. I noted these observations for two years until I could
test my hypothesis."
"On April 15, 1949, a GI Medical student
with arthrosis arrived in our clinic. For 3 weeks he'd had terrible pains and
blocked articulation. I explained my idea about Novocain to him and after receiving
his permission, gave him an intra-arterial injection with 1% Novocain. His knee
was mobile immediately and he could flex his leg outright. What happiness! I administered
this treatment for another two weeks, after which he completely recovered."
"There was a nice park close to the clinic in Timisoara, and one April
afternoon while I was there I noticed an old man. He was leaning on his crutches
and when sitting down, he laid his head in his hands. I later saw him in one of
Van Gogh's paintings! He embodied despair. My attention then turned to an old
couple who was walking with small steps, patiently leaning on one another. They
did not talk, but their dry wrinkled faces told enough about their many years.
Their gait was a symbol of their fraternity and support they have given, and will
continue to give, to each other for the rest of their lives."
"I
then said to myself, why can't I help these people? Why do they have to suffer
such pain and suffering? If this young man had started to walk after the injections
I had given him, maybe these people could be helped? They could smile again and
regain their own sure steps." "I did not go to Bucharest at the end
of the week as I had been doing on the weekends.
Instead I returned to
this park. All I could focus on was old people. I was overwhelmed with age; I
began to feel an unusual sympathy. Something had touched me deep down, and I began
my quest. At night I thought about the Novocain shots Loriche had administered
around wounds. If such rapid healing occurred, couldn't it benefit these people
as well? I became obsessed." "After doing pharmacodynamic research in
1946 with Dr. Danielopolu, this conviction crystallised in my mind between 1947-1949.
I was using Novocain to treat bronchial asthma according to Dos Gahali's method
and to treat arthritis and emboias according to Loriche's method."
"I practically ran to Bucharest with my results! Dr. Danielopolu advised
me to share this with Parhon immediately. His words to me were, "Novocain
has an effect on aging. You should carefully carry out this research. Come back
to Bucharest and lead our Experimental Department here. I'll make all the arrangements,
just say you'll come." I agreed and in a few months I was back in Bucharest."
This adventure that began in Timisoara continued in Bucharest. But it was
here that the struggle really began. In order to clear up the Novocain mechanism
of action in arthritis, Aslan followed its effects on experimental arthritis induced
by formaldehyde (according to Seyle-Brownlee's method).
"In the
fall of 1949, I wanted to present my first observations to the Academy of Medicine.
It was then that I realised the envy-taking place among my colleagues, and how
it was increasing. In a chorus, Milcu, Lupu, Nicolau and Benetato were adamantly
against it. "You need at least 25 cases" they argued. Finally, they
refused to include my research in the agenda being set for the Academy's meetings.
It doesn't matter, I told myself, Alzheimer presented his observations on a single
case, and Hodgkin on only six!"
"After Parhon left the Institute
of Endocrinology, those that followed caused me much frustration. (They did, however,
do one good thing, for which I want to thank them, they agreed with my resignation
and return to Bucharest)."
"With the passing of time I learned
that the opposition made me more and more ambitious. I knew that I was right and
I had to prove it. Life would be too dull without controversy, and in my case,
unfortunately, the controversies overstepped the bounds of academic dispute. All
of this doesn't matter now, I forgave them many years ago."
"It
was the co-operation with Parhon that does matter. He was very good to me and
was convinced by the results I was obtaining. He was my moral support, and it
is because of him that I continued with my research."
As soon as Aslan
began publishing and sharing her method, more and more people, most of them ill,
started to visit the Institute. The Institute, situated in an anonymous place,
gradually became the Mecca of the ill.
Scientists came to learn from
her as well as to undergo treatment. Some remained perplexed, listening to the
testimonies of the old people who had regained the joy of life, returned to their
favourite activities, found peace in their battles with insomnia.
More
importantly, they found their place in society, a society who before had alienated
and repulsed by them. Their spoken and written words are proof of the effectiveness
of her treatment, method and product, Gerovital-H3, which had bought so much relief
and hope to the suffering.
Many physicians came to the Institute for
training in gerontology and geriatrics, and to learn Aslan's method. In return,
Aslan visited them in their countries to acknowledge and celebrate their results.
With special appreciation, she remembered Dr. Marion Bucker Bode of Germany. Besides
leading a center of geriatrics, she also had serious concerns for research. She
talked also of Dr. Pop Michel of Cyprus, these and many others, were considered
her disciples in the fight against aging.
Some of the many testimonials
After visiting the Institute in September of 1958, Academician R. Bacov, Director
of the Pavlov Institute in Moscow, wrote, "I found the activity carried out
at the Institute of Professor Aslan to be very interesting. The problem they focus
on fascinates the world. I think Professor Aslan has found a real way to maintain
the activity of the nervous system and to prolong the normal functioning of the
entire organism. I myself am convinced that Aslan's method is a success. Thank
you for the wonderful demonstration of your results."
Robert A.
Homes, MD, chief physician in a hospital in Washington D.C., confessed that he
learned much from Aslan's revolutionary treatment. Hollings E., Senator S.C.,
Washington D.C., expressed his admiration for a real mother nature, as well as
Senator Howard W. of Nevada, who remarked on the wonderful work in such an important
field.
Professor Aslan thoroughly studied and diversified the research,
a fact that was noted in the pharmacology department of Harvard University as
well.
These were world-wide acknowledgements, the Minister of Health
in Belgium, Nameche Louis, stated that he was "impressed by the social action
developed by Aslan and convinced of the prophylactic results."
Ever
since 1966, Lord Amulree of London appreciated "the work Aslan developed
in order to cover all of Romania with a network of care centers for the elderly.
These could very well be imitated by other countries and I hope this wonderful
work by Professor Aslan will be very wide spread."
Dr. Iderwal de
Carvalbo, Professor of psycho-pathology at the Sao-Paulo University in Brazil
was "full of admiration for all he saw and felt at the Institute when he
personally noted the stateliness of Aslan's work and the magnificent results in
treating aging with Gerovital-H3 and Aslavital."
From the Institute
of Geriatrics and Gerontology of the University of Florence, Italy, Professor
Francesco Antonini, "admired the work carried out with such intelligence."
A letter of gratitude from Professor Mario Giacorezzo from the Medical Clinic
of Rome University, thanked Aslan "for this masterly lesson."
Journalists, writers and poets whose fantasy took them beyond the limits of reality
soon visited the Institute seeing the results in old patients. For example, Galina
Seredrinkova wrote, "Faust's dream, the alchemists fight for life has been
solved by the well known woman of our century, Ana Aslan. The gratitude and enthusiasm
towards her talent and her deep scientific thinking includes anybody between the
walls of her institute."
A news journalist by the name of A. Umar,
considered Aslan's results not only prestigious for Romania, but for the entire
world.
During her life, Aslan received thousands of letters. They came
from the most remote parts of the world. Sometimes the letters were directed with
no address, but a simple "Ana Aslan" on the envelope. The country and
address was not necessary, the entire world knew of her! In most letters, patients
expressed their thanks, for regaining strength, hope and confidence. They expressed
their gratitude for her competence and devotion.
She had four secretaries
who helped her answer each and every one. They had a difficult job, working in
the rhythm and time that Aslan demanded. She did not consider this impressive
correspondence as simple politeness and responsiveness, but rather as a constitutive
part of her own medical activity as a doctor. The exchange with research institutes,
such as the "Institute of Aging" in the United States and in Kiev, meant
contact.
From her travels and fame, Aslan made friendships everywhere. Many
of them became patients and followed her treatment for years and years. One of
these was Mr. Hans Matguart of Germany; he was a man of remarkable culture, honour
and honesty. After he learned of Aslan's death (a month after she had actually
died), he took a plane to Bucharest. He went to her grave and quietly remained
there for some time, as homage and out of respect.
He went on to address
me; "It is a pleasure for me to speak about Professor Ana Aslan, as she was,
in my opinion, a world authority and a remarkable person. My first encounter with
her took place in 1982. Ana was herself an old woman, but yet maintained all of
her mental capacity. Her long medical experience proved very useful. Ana was also
being treated with Gerovital-H3. Her intellectual capacity, maintained to the
end of her life, is proof of the drug's success." "I had begun my treatment
(Aslan's therapy) on August 12, 1980 and continued without an interruption.
She herself personally cared for me. She examined me and decided on which
type of therapy. For ten years, at regular intervals, I have been treated with
Gerovital-H3 by injections and by pills. I am now 76 years old; therefore I started
therapy when I was 65. Since then, I have continued leading negotiations in my
field and making all the necessary decisions about my activities. Would I still
if I wasn't using Gerovital-H3? I definitely say no!"
"In the
last 10 years I have accomplished my daily tasks with great joy. When we think
that the normal man retires at 65 or earlier, then these 10 years are even more
astonishing. I have held honorary positions and been appointed several times as
president of different organisations. This activity is proof of my capacity. It
should also be mentioned that in the last 10 years I have also had no serious
disease, more proof of healthy conditions due to Aslan's therapy."
"Throughout these 10 years I have often talked with others in this long term
treatment, and not once have I heard a negative word. Of course this therapy cannot
make miracles alone. Positive results only appear when regular treatments are
given and the physician one is dealing with is seen regularly."
"Above all, I hope her knowledge will be spread to all the people in this
country and to all of human-kind."
During this visit, Mr. Matquart was
intrigued and puzzled about why her death had not been immediately announced.
"Ana belonged to mankind, not only to Romania. Surely, Belu cemetery would
have been full with people from all over the world?" But under communism,
the people of Romania had no possibility to taste and to know of Ana Aslan's international
success.
Biological basis of Gerovital-H3 treatment
Ana Aslan at the Institute of Gerontology and Geriatrics in Bucharest, Romania
experimented with Gerovital-H3 between 1951 and 1958. Since 1951, Aslan stopped
the use of hydrochloric-procaine; the research results materialised a different
product with a new formula- Gerovital-H3. In the new formula, adding benzoic acid
to procaine and inducing a greater access of procaine into the hydrophobic cellular
compartments modified the pharmacological action of hydrochloric-procaine.
Between Gerovital-H3 and hydrochloric-procaine there is a difference of pharmacological
action. Hazard showed that the procaine-based product has a stability of 6-months,
whereas the Aslan product has a much increased stability of 2 years and 6-months.
Once introduced into the human body, the procaine molecule is hydrolysed
by procainestherase into two metabolical fractions; Paraaminobenzic acid (PABA)
and Diethylaminoethanol (DEAE). The absorption of the two metabolites is better
when they result from the in-vivo hydrolysis of Gerovital-H3 than administered
as such. The absorption takes place in a competitive manner, which means that
the two metabolites compete for the active sites or mechanism that govern the
absorption. The DEAE's absorption is particular to the brain as compared to other
organs.
The procaine from Gerovital-H3 has a greater capacity of wadding
the medium (pH), due to benzoic acid, reducing the degradation speed of the product.
DEAE splits into Ethanolamine, Glycine and Urea. Ethanolamine enters the synthesis
cycle of Choline and then acetylcholine. In the case of Gerovital-H3, the chromatographic
techniques showed that there are intact procaine molecules in the blood and heart
of experimental animals 6 hours after the product was administered. There are
two possible explanations for the important difference in the procaine metabolism.
It is considered that hydrochloric-procaine is differently metabolised depending
on the pH of the solution. At a pH of 7, the procaine is permeated "en mass"
into the blood, but at a pH of 3.3 the procaine is gradually set free from the
blood.
An acid solution will decrease the sudden release of the substance,
a quality that Gerovital-H3 possesses. Cohen (1) shows that benzoic acid will
arrange itself in space in such a manner that it protects the procaine molecule
at its weak point from the action of procainestherasis. Important are also the
K ions, which amplify the procaine action at the level of the nervous, and the
muscular system (2). Gordon (3) has compared Gerovital-H3 and Procaine and found
that there are significant statistical differences in favour of Gerovital-H3.
The experiments carried out by Aslan (4) showed significant differences between
Gerovital-H3 and Procaine inducing the vascular conditioned and unconditioned
reflexes in old patients.
Gerovital-H3 acts upon the human body both
under the form of an intact molecule and through the hydrolysis products PABA
and DEAE, which participate in the regulation of the intermediary metabolism.
Gerovital-H3 favours the acetylcholine synthesis and it is a source of folic
acid. In fact, a series of researches suggest the hypothesis that procaine, by
means of the PABA, can stimulate the intestinal flora and the production of folic
acid, vitamin K and tyramine. The cellular effect of the Aslan product bears different
characteristics and dimensions regarding the organ in question and its role within
the body. The improvement of the superior nervous activity presents a particular
importance. Yau (4) made a pharmacological study upon Gerovital-H3 and summarised
its basic mechanism as:
*Gerovital-H3 competitively and reversibly inhibits
monoamineoxidase (MAO).
*Gerovital-H3 acts as an antidepressive through the
modification of the monoamine level in the brain.
*Gerovital-H3 is very selective
in the oxidase desamination inhibition.
*Gerovial-H3's oxidative desamination
of monoamine is done in such a way as to eliminate the hyper-blood-pressure peak,
so typically present after administering of other MAO inhibitors.
*Gerovital-H3
is considered to play a role in maintaining the physiological status of the nervous
cell membrane, restoring the equilibrium between the processes of excitation and
inhibition at the level of the cortical and subcortical systems.
*Gerovital-H3
exerts an important regulatory action upon the nervous vegetative centers. Further
experiments reveal procaine's anabolic action. Studies on Infusoria (Colpidium
colpoda and Vorticella) show the proliferation of cells as a result of a weak
procaine solution (6).
The investigations on rats drew the attention
of procaine's anabolic affects improving the quality of the hair. Berger obtained
similar results with 6mg procaine / Kg bodyweight in a study on 3-month old rats
(7). On the other hand, Verzar used 25mg procaine / Kg bodyweight (the amount
which inhibits oxidoreduction) and did not notice any modification (8). In order
the solve these contradictory results, Aslan initiated a study on 1800 white rats
treated with Gerovital-H3 (9). The results pointed out an improved general tropicity,
an increased resistance to pulmonary disease and less myocardial modifications.
Fewer spontaneous tumours occurred in the treated group as compared against the
controls.
Gerovital-H3 action upon the lipid mechanism is reflected by
the lypotrope, heparinoid and lypoconverting characteristic (10). Aslan's procaine-based
product exerts its effects on the atherogenesis process by several mechanisms:
*Gerovital-H3 diminishes the level of plasmatic lipoproteins and lipids.
*Gerovital-H3
exerts an effect on the erythrocyte membrane (an increase in membrane fludity
and a protection against osmotic hemolisis).
*Gerovital-H3 has an anti-oxidant
mechanism that reduces the oxidative stress exerted on the membrane structure.
Russu et col. Found that Gerovital-H3 exerts an inhibition on the generation of
the superoxide radical in a non-enzymatic system (11).
It has been shown
that Gerovital-H3 action on the lipid metabolism results in modifications in the
serum total cholesterol, changes of the lipoprotein fractions ratio and changes
to the unsaturated fatty acids content (11).
The international confirmations
Mention must be made of the fact that the research concerning Gerovital-H3 therapy
has been simulated in over 500 medical and scientific publications.
The experiments
utilising the original Aslan product and method confirm the efficiency and efficacy
of Gerovital-H3.
The data presented at the 10th Congress of the International
Association of Gerontology in Jerusalem in 1975, and at the European Congress
of Clinical Gerontogy in 1977, made available new evidence of the efficiency of
Gerovital-H3.
The work of the special session at the Jerusalem Congress
regarding old age pharmacology were dominated by the research focussed upon the
mechanism of Gerovital-H3 action.
A special interest was generated by
the mechanism of Gerovital-H3's action, particularly from several American scientists
who presented papers of double-blind placebo controlled trials. Among them was
Professor William Zung from Duke University, North Carolina who in his study applied
the treatment for 28 days on his patients who were suffering from depression (12).
One group of patients aged 60 were submitted before, during and after the
treatment to a battery of psychological tests. Professor Zung, a well known and
respected author of psychological tests, proved the Gerovital-H3 efficiency in
the treatment of depression. Within the same session, the American authors, M.
Kurland and M. Hayman from Palm Springs, California, presented the double-blind
results performed with Gerovital-H3 on 63 patients suffering from depression and
aged 45 to 80 (33 using Gerovital-H3 and 30 using placebo). Under observation
there were several types of depression; manic-depression, reactive depression,
organic cerebral depression, chronic reactive depression and alcoholic depression.
The results proved that Gerovital-H3 efficiency in all the tests applied,
the differences between the two groups showed a great statistical significance
(p>0.001).
Particularly valuable results were communicated by McFarlane
MD who proved that Gerovital-H3 inhibits MAO (13). It is a known fact that the
MAO levels increase with advancing age (14). McFarlane certifies the lack of any
adverse reactions with Gerovital-H3 and he also confirmed that Gerovital-H3 is
a reversible and competitive MAO inhibitor.
The success enjoyed by Gerovital-H3
at the Jerusalem International Congress in June 1975, was remarked upon by Professor
Nathan Shock (USA) in the closing speech of the Congress. That recognition came
shortly after another world-wide known gerontologist, Alex Comfort (England),
in an article published in the magazine "Mechanism of Ageing and Development",
where he made positive remarks upon Gerovital-H3 and Aslan's method.
On the
occasion of the International meeting "Medizinischewoche" in Baden Baden,
Germany in November 1983, whilst concluding the Gerontology and Geriatrics section,
Professor Paul Luth said "The Aslan method and treatment represent the most
efficient therapeutic producure in Geriatrics." (15)
Aslan's
method of prophylactic and curative treatment with Gerovital-H3
As a medical
professor from 1947 to 1949, Ana Aslan was inspired by the works of Lorich. Aslan
started administering procaine in cases of arthritis and in trophic troubles of
the extremities with sometimes spectacular results (1).
This is what
Ana Aslan declared from the very beginning; "After one injection in the femural
artery given to a patient with embolism at the level of the inferior extremity,
I noticed the almost instantaneous disappearance of pain. Then, for the first
time, I had the idea of applying the same method in certain diseases with acute
pain, which produce immobilization and thus long-lasting work incapacity."
Like other great discoveries, the clinical observation facts did not fail
Aslan, as they represented the beginning of a period of original and fundamental
studies which contributed to the prophylaxis and treatment of aging and chronic
disease. Thus, in that period, another clinical observation was pointed out by
the patients who stated that after the injections (given into the artery of the
extremities), pain was relieved in all the body. "I believe, a general effect
was obtained," concluded Aslan.
Starting in 1949, Aslan began applying
her treatment in a nursing home. Besides an improvement of the local phenomena,
she noticed that the physical and psychical state of the old men was becoming
better. That was the time when Aslan initiated experimental research which had
particularly favourable effects on all the treated animals.
I want to
emphasize that, besides introducing the procaine treatment against the aging process
and degenerative illnesses Aslan had other original contributions lying at the
base of the treatment and method bearing her name.
*Aslan introduced
long-term procaine therapy.
*Aslan used procaine in intramuscular injections
according to her own schedule, which represented a true therapeutic novelty, since
previously procaine had only been used for local anaesthesia, or in short-term
cures injected either subcutaneously, intravenously or, more rarely, intra-arterially.
The special moment arrived when procaine was prepared to the new formula
now known as Gerovital-H3. This is more active and has practically no side effects
if administered in therapeutic doses.
Gerovital-H3 was experimented with
at the Institute of Gerontogy and Geriatrics in Bucharest, between 1951 and 1958.
In 1957, Aslan started comparative investigations to establish the effectiveness
of the oral treatment. To achieve the same results like in the parentral treatment,
the oral dose has to be doubled.
I must also state that at the Bucharest
Institute, to evaluate the effects of Gerovital-H3 treatment, since 1952, a clinical
study has been initiated. This study, due to the thousands of patients observed
over a 25 year time scale makes this clinical study unique in the world. Gerovital-H3
is a complex drug acting like the procaine molecule with its two hidrolisis products;
PABA and DEAE. The addition of benzoic acid, potassium and disodium phosphate
increase the effects of Gerovital-H3 biotrophic treatment.
Indications
for Gerovital-H3
Gerovital-H3 is indicated for people older than
40 years in order to retard the aging process and as a preventative and curative
treatment for chronic degenerative diseases. Gerovital-H3 has been shown to be
efficacious in all the following:
*moderate and light depressive states.
*in troubles concerning attention, concentrating, cognitive processes and in balancing
the neurovegative distinies.
*chronic fatique syndrome.
*sleep disorders.
*tegument distrophias, trophic ulcers, atonic wounds.
*osteoarthritis, degenerating
rheumatism, osteoporosis and during fracture consolidation periods.
*sexual
management and improving sex drive
*Gerovital-H3 is an active anti-aterogenous
factor and recommended in cerebral and peripheral artherosclerosis and in the
treatment of post-infarct and hemiplegia consequences.
*Parkinson and Parkinson
syndromes.
*Gerovital-H3 ameliorates the hair resistance and quality, repigmentation,
reduces the alopecia (hair loss), head skin seborrhea and helps eliminate the
pruritus.
*due to the inhibition on the generation of the superoxide radical,
Gerovital-H3 is a powerful antioxidant, a free radical quencer.
Outcome
of Gerovital-H3 treatment
Aslan's treatment produces a general transformation
of the organism manifested as follows:
*desire to be active and to live,
better memory, enhanced concentration ability and attention, improved optimism.
*improved affective tone and psychic and vegetative balance.
*increased self-caring
abilities and exercise capacity.
*more ability to cope with the environment
and increased resistance to infections.
*balanced endocrine functions with
oestrogens reappearance and androgen reactivation.
*improved visual, auditive
and olphactive acuity.
*diminished extrapyramidal rigidity, improved gait
and increased mobility.
*better skin, nails and mucous trophicity.
*hair
growth stimulation with a tendency to repigmentate the hair and a more trophic
aspect.
*better blood vessel reactivity.
*the alleviation should also
be mentioned of the clinical symptoms of the chronic diseases; chronic rheumatism,
atherosclerosis, bronchial asthma, psoriasis, vitiligo, varicose ulcers.
*improves
the quality of life retarding the rhythm of aging and preventing the chronic diseases.
*improves the sex drive.
Administering method for Gerovital-H3
The long term treatment with Gerovital-H3 has been extensively established with
Aslan et col. For over 40 years at the National Institute of Gerontogoy and Geriatrics
in Romania, in compliance with Aslan's methods.
At the beginning, Gerovital-H3
was administered only as injections. The tolerance has always been tested before
starting the treatment; one subcutaneous injection of 1ml on the first day, followed
by an intramuscular injection of 2ml the next day.
If no local or general
reactions occur, proper treatment can be started. In the experience of more than
300,000 patients that completed this treatment in Romania, an intolerance only
occurred in 1 in 7000 cases.
In 1957, Aslan started clinical and experimental
comparative investigations in order to establish the effectiveness of the oral
administration.
The dose of active substances had to be doubled to achieve
the same results as in the parenteral treatment. Considering this fact and the
difficulty raised by the accurate management in certain patients, Aslan established
a combined schedule made up of both oral and parenteral approaches as follows:
*PREVENTATIVE Treatment of chronic diseases and aging consists of 4 courses of
12 injections and 4 courses of 24 pills, ie, one course of 12 injections over
4 weeks (ie, 3 injections per week), a 4-week break then one course of 24 pills
over 12 days (one pill twice daily between meals), a 2-week break and then the
cycle is resumed.
*Starting from the age of 40 years, the prophylactic treatment
with pills only is recommended in a series of 25 tablets during the first 12 days,
with an interval of 2 months; 1st day, 1 tablet/ day, 2-hours after breakfast,
increasing to the 12th day when 2 tablets per day are taken, (again 2-hours after
meals, for example one at 10AM and another at 4PM). There should a series of 5
treatment courses in the year, which should be increased to 6 per year for persons
over the age of 65.
*CURATIVE Treatment in chronic diseases requires 6 course
of 12 injections, and 5 courses of 24 pills, yearly, ie, one course of 12 injections
over 4 weeks, a 2-week break, one course of 24 pills over 12 days (one pill twice
daily between the meals); 2 week break. The cycle is then resumed.
Depending
upon the outcomes the physician and patients can either shorten or extend the
breaks. The first and second course of injections can be administered daily in
order to study the individual reactivity.
Gerovital-H3 treatment can be individualised
according to the disease/ diseases accompanying the aging and the patients biological
age.
In arteritis, actively influenced by Gerovital-H3, the route of
administration is intra-arterial. Aslan recommended the intra-arterial route in
arthrosis and arthritis, especially when the knee joint is involved, and the intravenous
route for cerebral spasms.
Contraindications
Gerovital-H3
should be avoided by anyone suffering or utilising the following;
*allergy
or sensitivity to Gerovital-H3 (or Novocain).
*Gerovital-H3 cannot be used
together with eserine or prostigmine.
*Gerovital-H3 can not be used at the
same time as sulphamides.
*Gerovital-H3 should not be used with an antibacterial
treatment.
Side effects
Gerovital-H3 side effects are relatively
uncommon and may occur principally only after injections, but the frequency is
very reduced (according to the statistics there is 1 case for every 7000 patients).
The minor side effects consist of a heating sensation and metallic taste, these
effects disappear during the treatment.
The major side effects are related
to the skin; macular eruption, rash and itching which determine the interruption
of the treatment and the remake of the tolerance test (1ml injected id.) after
the eruption has disappeared. The treatment of the side effects consist of the
administration of the usual antiallergic drugs if the eruption persists after
the arrest of Gervotial-H3.
In spite of its monoamineoxidase (MAO) inhibitor
character, Gerovital-H3 does not interfere, as the convential MAO inhibitors do,
with the Tyramine from food (ed.- commonly called the cheese affect), which means
there is no known incompatibility with Gerovital-H3 and food. The interaction
with sulphamides is because of the competition on the bacterial metabolism. Overdose
may occur only after 400mg in iv rapid injection and the treatment is the same
as for any acute intoxication.
Reference; (1). Loriche R., Lafontaine
R.: De l'emploi des injections intra-arterielle de novocaine dans les formes daouloureuses
des obliterantes. Presses Medicale, 1953, 17:327.
References
(1). Cohen S., Ditman K.S. Effects of Gerovital-H3 on Elderly
Depressive Patients. Int. Smposium of Gerontology, Bucharest, 1972.
(2). Teitel
A., Gane P., Stroescu V., Steflea D., About the Mechanisms of Procaine. Studies
of Fisiology, Bucharest, 1962, 4, 351-360.
(3). Gordon P., Fudema A., Abrams
A., Effects of Romanian and American Procaine Preparations on Certain Physiological
Aspects of Aging. Gerontologist II, 1962, p.9, Gerontologist, 1965, 20, 2, p114-150.
(4). Ana Aslan; Gerovital-H3 Therapy in the Prophylaxis of Ageing. Rom. J. Geront.
Geriatrics. Bucharest, 1980, 1,1 p5-15.
(5). Yau M.T. Gerovital-H3, Monoamineoxidase
and Brain Monoamines. Symposium on Theoretic Aspects of Aging, 1974, Miami, Florida.
(6). Parhon C.I., Ana Aslan, L'action de la Vitamine H1 et H2 sur la proliferation
de la cellule animale. Bull. Acad. Rom. Bucharest, 1957, 9,1, 137.
(7). Berger
P; Innocuite du traitment chronique a la procaine chez le rat en croissance. C.R.
So. Biol. 1960, 154,959.
(8). Verzar F. Note on the influence of prcaine,
PABA and DEAE on the aging of rats. Basel, 1959, Gerontology 3,6, 350-355.
(9). Ana Aslan et col. Long term treatment with Gerovital-H3 in Albino rats. J.
Gerontology, 1965, 20,1.
(10). Ana Aslan, G. Enachescu. Reseaches on the Anti-thrombophilic
activity of Gerovital-H3 treatment. Rom. J. Geront. Geriatrics, 180, 1, 2, 195-246.
(11). Russu C et col. Antioxidant and lipid lowering effect of original procaine
based product Gerovital-H3. Book of abstracts. The 16th Congress of the Internatonal
Association of Gerontology, p217.
(12). Zung W.W.K., Wang H.S. Clinical trials
of Gerovital-H3 in the treatment of depression in the elderly. 10th Int. Congress
of Gerontology, 1975, Jerusalem.
(13). McFarlane MD Gerovital-H3 therapy;
Mechanism of inhibition ofmonoamineoxidase. J. of American Geriatrics Society.,
1974, XXII/8, p365-371.
(14). Robinson D.S. et al; Aging, monoamine and monoamineoxidase
levels, 1972, Lancet, 1, 0290.
(15). Luth P. Aslan therapie mit Gerovital-H3.
Zeitschrift fur Algemenmedizin, 1984, 60, 27, p1162-1164.
DISCLAIMER:
ALL INFORMATION IS EDUCATIONAL AND PROVIDED UNDER IAS TERMS AND CONDITIONS. IT
DOES NOT, AND SHOULD NOT, REPLACE THE ADVICE OF YOUR PHYSICIAN.
Gerovital
H3 Home
Gerovital
H3 Ingredients Purchase
Gerovital H3
print
version FULL
SUMMARY ABOUT SELECT GEROVITAL H3 (PDF Format)
 |
Please
note that it is required that you have Acrobat Reader installed on your system
to view the above documents.
You can download the latest version by clicking
here. | 
|
